表紙:ディスレクシア治療および診断市場 - 2027年までの予測
市場調査レポート
商品コード
1074668

ディスレクシア治療および診断市場 - 2027年までの予測

Dyslexia Treatment Market - Forecast to 2027

出版日: | 発行: Market Research Future | ページ情報: 英文 169 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=136.22円
ディスレクシア治療および診断市場 - 2027年までの予測
出版日: 2022年05月10日
発行: Market Research Future
ページ情報: 英文 169 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のディスレクシア治療および診断の市場規模は、今後7.10%のCAGRで拡大し、2027年末までに385億1,467万米ドルを超えると予測されています。

当レポートでは、世界のディスレクシア治療および診断市場について調査し、市場の概要とともに、タイプ別、治療・診断別、エンドユーザー別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場のイントロダクション

第3章 調査手法

第4章 市場力学

  • 概要
  • 促進要因
    • ディスレクシアの有病率の上昇
    • ディスレクシアを治療するためのアプリ開発活動の強化
    • 仮想現実ベースの教育用ソフトウェアの増加
  • 抑制要因
    • ディスレクシアとその症状についての認識の欠如と過小診断
  • 機会
    • 学校、大学、非営利団体との連携

第5章 市場要因分析

  • バリューチェーン分析
  • ポーターのファイブフォースモデル
  • COVID-19の影響
  • ディスレクシアの診断
  • ディスレクシアの治療
  • 標準のペーパーテストと電子版

第6章 世界のディスレクシア治療および診断市場、タイプ別

  • 概要
  • 音韻性ディスレクシア
  • 表層性ディスレクシア
  • その他

第7章 世界のディスレクシア治療および診断市場、治療・診断別

  • 概要
  • 治療
  • 診断

第8章 世界のディスレクシア治療および診断市場、エンドユーザー別

  • 概要
  • 専門センター
  • 在宅ケア
  • 病院とクリニック
  • その他

第9章 世界のディスレクシア治療および診断市場、地域別

  • 概要
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • オーストラリア
    • 韓国
    • その他
  • その他の地域
    • ラテンアメリカ
    • 中東
    • アフリカ

第10章 競合情勢

第11章 企業プロファイル

  • PFIZER INC.
  • SPEECHIFY INC.
  • JUBILANT PHARMA LIMITED
  • LINGIT AS
  • SOLI
  • NOVARTIS AG
  • LYFTA
  • GLAXOSMITHKLINE
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • ELI LILLY & COMPANY
  • RPG LIFE SCIENCES LTD
  • HOPALAI D.O.O.

第12章 付録

図表

LIST OF TABLES

  • TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
  • TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
  • TABLE 3 APPLICATION DEVELPOPED SPECIFICALLY FOR DYSLEXIA
  • TABLE 4 FREE APPS FOR DYSLEXIA
  • TABLE 5 DYSLEXIA SCHOOLS IN CANADA
  • TABLE 6 DYSLEXIA SCHOOLS IN THE UK
  • TABLE 7 DYSLEXIA SCHOOLS IN THE UK
  • TABLE 8 DYSLEXIA AND LEARNING DISABILITIES TESTS FOR PRE-SCHOOLERS (BIRTH - 5 YEARS):
  • TABLE 9 GLOBAL: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY SHOULDER TYPE, 2018-2027 (USD MILLION)
  • TABLE 10 GLOBAL: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY PHONOLOGICAL DYSLEXIA, 2018-2027 (USD MILLION)
  • TABLE 11 GLOBAL: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, FOR SURFACE DYSLEXIA, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 12 GLOBAL: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, FOR OTHERS, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 13 GLOBAL: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)
  • TABLE 14 GLOBAL: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, FOR TREATMENT, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 15 GLOBAL: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 16 GLOBAL: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, FOR MEDICATIONS, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 17 GLOBAL: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, FOR MEDICATIONS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 18 GLOBAL: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, FOR ANTIHISTAMINES, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 19 GLOBAL: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, FOR CENTRAL NERVOUS STIMULANT, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 20 GLOBAL: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, FOR ANTI-MYOCLONIC, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 21 GLOBAL: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, FOR ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) DRUG, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 22 GLOBAL: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, FOR OTHERS, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 23 GLOBAL: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, FOR TOOLS, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 24 GLOBAL: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, FOR TOOLS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 25 GLOBAL: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, FOR E-READERS AND TABLETS, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 26 GLOBAL: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, FOR APPS, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 27 GLOBAL: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, FOR SMARTPENS, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 28 GLOBAL: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, FOR OTHERS, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 29 COMMON CLINICAL TESTS PERFORMED TO DIAGNOSE DYSLEXIA
  • TABLE 30 GLOBAL: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, FOR DIAGNOSIS, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 31 GLOBAL: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 32 GLOBAL: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, FOR PAPER-BASED, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 33 GLOBAL: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, FOR DIGITAL-BASED, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 34 GLOBAL: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 35 GLOBAL: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, FOR SPECIALTY CENTER, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 36 GLOBAL: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, FOR HOME CARE, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 37 GLOBAL: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, FOR HOSPITALS & CLINICS, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 38 GLOBAL: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, FOR OTHERS, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 39 GLOBAL: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 40 NORTH AMERICA: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
  • TABLE 41 NORTH AMERICA: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 42 NORTH AMERICA: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)
  • TABLE 43 NORTH AMERICA: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 44 NORTH AMERICA: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, FOR MEDICATION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 45 NORTH AMERICA: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, FOR TOOLS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 46 NORTH AMERICA: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 47 NORTH AMERICA: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 48 US: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 49 US: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)
  • TABLE 50 US: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 51 US: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, FOR MEDICATION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 52 US: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, FOR TOOLS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 53 US: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 54 US: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 55 CANADA: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 56 CANADA: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)
  • TABLE 57 CANADA: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 58 CANADA: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, FOR MEDICATION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 59 CANADA: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, FOR TOOLS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 60 CANADA: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 61 CANADA: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 62 EUROPE DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 63 EUROPE DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)
  • TABLE 64 EUROPE DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 65 EUROPE DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR MEDICATION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 66 EUROPE DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR TOOLS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 67 EUROPE DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 68 EUROPE DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 69 GERMANY DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 70 GERMANY DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)
  • TABLE 71 GERMANY DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 72 GERMANY DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR MEDICATION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 73 GERMANY DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR TOOLS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 74 GERMANY DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 75 GERMANY DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 76 UK DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 77 UK DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)
  • TABLE 78 UK DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 79 UK DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR MEDICATION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 80 UK DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR TOOLS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 81 UK DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 82 UK DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 83 FRANCE DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 84 FRANCE DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)
  • TABLE 85 FRANCE DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 86 FRANCE DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR MEDICATION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 87 FRANCE DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR TOOLS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 88 FRANCE DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 89 FRANCE DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 90 ITALY DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 91 ITALY DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)
  • TABLE 92 ITALY DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 93 ITALY DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR MEDICATION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 94 ITALY DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR TOOLS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 95 ITALY DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 96 ITALY DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 97 SPAIN DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 98 SPAIN DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)
  • TABLE 99 SPAIN DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 100 SPAIN DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR MEDICATION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 101 SPAIN DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR TOOLS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 102 SPAIN DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 103 SPAIN DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 104 REST OF EUROPE DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 105 REST OF EUROPE DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)
  • TABLE 106 REST OF EUROPE DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 107 REST OF EUROPE DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR MEDICATION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 108 REST OF EUROPE DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR TOOLS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 109 REST OF EUROPE DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 110 REST OF EUROPE DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 111 ASIA PACIFIC: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
  • TABLE 112 ASIA-PACIFIC: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 113 ASIA-PACIFIC DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)
  • TABLE 114 ASIA-PACIFIC DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 115 ASIA-PACIFIC DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR MEDICATIONS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 116 ASIA-PACIFIC DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR TREATMENT, BY TOOLS, 2018-2027 (USD MILLION)
  • TABLE 117 ASIA-PACIFIC DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 118 ASIA-PACIFIC: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 119 CHINA: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 120 CHINA DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)
  • TABLE 121 CHINA DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 122 CHINA DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR MEDICATIONS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 123 CHINA DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR TREATMENT, BY TOOLS, 2018-2027 (USD MILLION)
  • TABLE 124 CHINA DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 125 CHINA: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 126 JAPAN: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 127 JAPAN: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)
  • TABLE 128 JAPAN: DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 129 JAPAN: DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR MEDICATIONS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 130 JAPAN: DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR TREATMENT, BY TOOLS, 2018-2027 (USD MILLION)
  • TABLE 131 JAPAN: DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 132 JAPAN: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 133 INDIA: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 134 INDIA: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)
  • TABLE 135 INDIA: DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 136 INDIA: DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR MEDICATIONS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 137 INDIA: DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR TREATMENT, BY TOOLS, 2018-2027 (USD MILLION)
  • TABLE 138 INDIA: DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 139 INDIA: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 140 AUSTRALIA: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 141 AUSTRALIA: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)
  • TABLE 142 AUSTRALIA: DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 143 AUSTRALIA: DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR MEDICATIONS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 144 AUSTRALIA: DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR TREATMENT, BY TOOLS, 2018-2027 (USD MILLION)
  • TABLE 145 AUSTRALIA: DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 146 AUSTRALIA: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 147 SOUTH KOREA: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 148 SOUTH KOREA: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)
  • TABLE 149 SOUTH KOREA: DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 150 SOUTH KOREA: DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR MEDICATIONS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 151 SOUTH KOREA: DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR TREATMENT, BY TOOLS, 2018-2027 (USD MILLION)
  • TABLE 152 SOUTH KOREA: DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 153 SOUTH KOREA: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 154 REST OF ASIA-PACIFIC: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 155 REST OF ASIA-PACIFIC: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)
  • TABLE 156 REST OF ASIA-PACIFIC: DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 157 REST OF ASIA-PACIFIC: DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR MEDICATIONS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 158 REST OF ASIA-PACIFIC: DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR TREATMENT, BY TOOLS, 2018-2027 (USD MILLION)
  • TABLE 159 REST OF ASIA-PACIFIC: DYSLEXIA TREATMENT & DIAGNOSIS MARKET FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 160 REST OF ASIA-PACIFIC: DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 161 REST OF THE WORLD: DYSLEXIA TREATMENT MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
  • TABLE 162 REST OF THE WORLD: DYSLEXIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 163 REST OF THE WORLD: DYSLEXIA TREATMENT MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)
  • TABLE 164 REST OF THE WORLD: DYSLEXIA TREATMENT MARKET, FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 165 REST OF THE WORLD: DYSLEXIA TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 166 REST OF THE WORLD: DYSLEXIA TREATMENT MARKET, FOR TOOLS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 167 REST OF THE WORLD: DYSLEXIA TREATMENT MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 168 REST OF THE WORLD: DYSLEXIA TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 169 LATIN AMERICA: DYSLEXIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 170 LATIN AMERICA: DYSLEXIA TREATMENT MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)
  • TABLE 171 LATIN AMERICA: DYSLEXIA TREATMENT MARKET, FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 172 LATIN AMERICA: DYSLEXIA TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 173 LATIN AMERICA: DYSLEXIA TREATMENT MARKET, FOR TOOLS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 174 LATIN AMERICA: DYSLEXIA TREATMENT MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 175 LATIN AMERICA: DYSLEXIA TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 176 MIDDLE EAST: DYSLEXIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 177 MIDDLE EAST: DYSLEXIA TREATMENT MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)
  • TABLE 178 MIDDLE EAST: DYSLEXIA TREATMENT MARKET, FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 179 MIDDLE EAST: DYSLEXIA TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 180 MIDDLE EAST: DYSLEXIA TREATMENT MARKET, FOR TOOLS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 181 MIDDLE EAST: DYSLEXIA TREATMENT MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 182 MIDDLE EAST: DYSLEXIA TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 183 AFRICA: DYSLEXIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 184 AFRICA: DYSLEXIA TREATMENT MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)
  • TABLE 185 AFRICA: DYSLEXIA TREATMENT MARKET, FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 186 AFRICA: DYSLEXIA TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 187 AFRICA: DYSLEXIA TREATMENT MARKET, FOR TOOLS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 188 AFRICA: DYSLEXIA TREATMENT MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 189 AFRICA: DYSLEXIA TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 190 MAJOR PLAYERS IN THE GLOBAL DYSLEXIA TREATMENT MARKET
  • TABLE 191 THE MOST ACTIVE PLAYERS IN THE GLOBAL DYSLEXIA TREATMENT MARKET
  • TABLE 192 NEW PRODUCT DEVELOPMENTS/LAUNCHES/PRODUCT LICENSING AGREEMENTS
  • TABLE 193 COLLABORATIONS/EXPANSIONS/PARTNERSHIPS/INVESTMENTS
  • TABLE 194 PFIZER INC.: PRODUCTS OFFERED
  • TABLE 195 SPEECHIFY INC.: PRODUCTS OFFERED
  • TABLE 196 JUBILANT PHARMA LIMITED: PRODUCTS/SERVICES OFFERED
  • TABLE 197 LINGIT AS: PRODUCTS OFFERED
  • TABLE 198 LINGIT AS: KEY DEVELOPMENTS
  • TABLE 199 SOLI: PRODUCTS/SERVICES OFFERED
  • TABLE 200 NOVARTIS AG: PRODUCTS/SERVICES OFFERED
  • TABLE 201 LYFTA: PRODUCTS/SERVICES OFFERED
  • TABLE 202 LYFTA: KEY DEVELOPMENTS
  • TABLE 203 GLAXOSMITHKLINE: PRODUCTS OFFERED
  • TABLE 204 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCTS/SERVICES OFFERED
  • TABLE 205 TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY DEVELOPMENTS
  • TABLE 206 ELI LILLY & COMPANY: PRODUCTS/SERVICES OFFERED
  • TABLE 207 RPG LIFE SCIENCES LTD: PRODUCTS/SERVICES OFFERED
  • TABLE 208 HOPALAI D.O.O.: PRODUCTS/SERVICES OFFERED  

LIST OF FIGURES

  • FIGURE 1 MARKET SYNOPSIS
  • FIGURE 2 MARKET STRUCTURE: DYSLEXIA TREATMENT & DIAGNOSIS MARKET
  • FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES
  • FIGURE 4 MARKET DYNAMICS: DYSLEXIA TREATMENT & DIAGNOSIS MARKET
  • FIGURE 5 DRIVERS: IMPACT ANALYSIS
  • FIGURE 6 RESTRAINT: IMPACT ANALYSIS
  • FIGURE 7 VALUE CHAIN: GLOBAL DYSLEXIA TREATMENT & DIAGNOSIS MARKET
  • FIGURE 8 VALUE CHAIN: GLOBAL DYSLEXIA TREATMENT & DIAGNOSIS MARKET
  • FIGURE 9 PORTER'S FIVE FORCES ANALYSIS: GLOBAL DYSLEXIA TREATMENT & DIAGNOSIS MARKET
  • FIGURE 10 GLOBAL DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY TYPE, 2020 & 2027 (USD MILLION)
  • FIGURE 11 GLOBAL DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY TREATMENT & DIAGNOSIS, 2020 & 2027 (USD MILLION)
  • FIGURE 12 GLOBAL DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY END USER, 2020 & 2027 (USD MILLION)
  • FIGURE 13 GLOBAL: DYSLEXIA TREATMENT & DIAGNOSIS MARKET SHARE (%), BY REGION, 2020
  • FIGURE 14 NORTH AMERICA: DYSLEXIA TREATMENT & DIAGNOSIS MARKET SHARE (%), BY COUNTRY, 2020
  • FIGURE 15 ASIA PACIFIC: DYSLEXIA TREATMENT & DIAGNOSIS MARKET SHARE (%), BY COUNTRY, 2020
  • FIGURE 16 REST OF THE WORLD: DYSLEXIA TREATMENT MARKET SHARE (%), BY COUNTRY, 2020
  • FIGURE 17 EXPANSION: THE MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL DYSLEXIA TREATMENT MARKET
  • FIGURE 18 BENCHMARKING OF MAJOR COMPETITORS
  • FIGURE 19 REVENUE OF MAJOR PLAYERS, 2020
  • FIGURE 20 MAJOR PLAYERS R&D EXPENDITURE, 2020
  • FIGURE 21 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 22 PFIZER INC.: SWOT ANALYSIS
  • FIGURE 23 JUBILANT PHARMA LIMITED: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 24 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 25 NOVARTIS AG: SWOT ANALYSIS
  • FIGURE 26 GLAXOSMITHKLINE: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 27 GLAXOSMITHKLINE: SWOT ANALYSIS
  • FIGURE 28 TEVA PHARMACEUTICAL INDUSTRIES LTD: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 29 TEVA PHARMACEUTICAL INDUSTRIES LTD: SWOT ANALYSIS
  • FIGURE 30 ELI LILLY & COMPANY: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 31 ELI LILLY & COMPANY: SWOT ANALYSIS
  • FIGURE 32 RPG LIFE SCIENCES LTD.: FINANCIAL OVERVIEW SNAPSHOT
目次
Product Code: MRFR/HC/6890-CR | March 2022

Market Overview

As per the MRFR analysis, the global dyslexia treatment market is projected to register a significant market expansion at a notable CAGR of 7.10% during the review period to surpass USD 38,514.67 million by the end of 2027. Research has shown that dyslexia happen due to the way the brain cerebrum processes data. So that is the reason perusing seems like such sluggish, difficult work. Individuals with dyslexia frequently track down ways of working around their handicap, so nobody will realize they're having trouble. This might save some humiliation, however, getting help could make school and peruse more straightforward. The vast majority are analyzed as children, yet it's to be expected for youngsters or even grown-ups to be analyzed.

The global dyslexia treatment market is expected to register a healthy market expansion owing to the highest market value of USD 23,682.69 million in 2020. The development of the worldwide dyslexia treatment market is driven by the rising predominance of dyslexia and expanding application improvement exercises to treat dyslexia and among others. However, it may, the absence of mindfulness about dyslexia, its side effects, and underdiagnosis is a limiting element for the dyslexia treatment market. Then again, coordinated effort with schools, universities, and non-benefit associations gives rewarding open doors to players working in the worldwide dyslexia treatment market.

Market Segmentation

The global Dyslexia Treatment Market has been classified in terms of type, application, end-user, and region.

The type of segment categorizes the market into Phonological Dyslexia, Surface Dyslexia, and Others. Based on Application, the market is bifurcated into Treatment and Diagnosis. The end-user segment has been classified in terms of Specialty centers, Home Care, Hospitals & Clinics, and Others.

Regional Analysis

The global dyslexia treatment market is classified, geographically into five major regions North America, Europe, Asia-Pacific, and the Rest of the World.

North America represented the biggest market portion of 5.79% is because of the presence of created medical services framework, positive government approaches, and presence of significant key organizations central command in the region, for example, Jubilant Cadista (US) and Speechify (US), and high predominance of dyslexia are driving the market in the area. For example, as per the Dyslexia Center of Utah, one of every five understudies, i.e., 15%-20% of the US populace, have a learning-based incapacity, most regularly dyslexia.

Europe represented a considerable share of the worldwide dyslexia treatment and analysis market. Like North America, Europe additionally faces a high commonness of dyslexia. Asia-Pacific is the quickest developing territorial market for the dyslexia treatment and conclusion market as it is growing quickly and has seen the rise of numerous players. There is likewise a high predominance of dyslexia driving the market development. As indicated by the Department of Biotechnology, in 2019, around 35 million kids in India were thought to be dyslexics. Moreover, provinces in the Asia-Pacific locales have additionally fostered their own dyslexia evaluation tests to accurately recognize the dyslexic populace inside the nation and give proper consideration.

Major Players

The key Companies mentioned in the dyslexia treatment market are Pfizer, Inc. (US), Novartis AG (Switzerland), Lyfta (UK), GlaxoSmithKline (UK), Teva Pharmaceutical Industries Ltd (Israel), Speechify Inc. (US), Jubilant Pharma Limited (Singapore), Lingit AS (Norway), Soli (UK), Eli Lilly & Company (US), RPG Life Sciences Ltd (India), Hopalai D.O.O. (Slovenia).

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

  • 2.1 DEFINITION
  • 2.2 SCOPE OF THE STUDY
  • 2.3 RESEARCH OBJECTIVE
  • 2.4 MARKET STRUCTURE
  • 2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

  • 3.1 DATA MINING
  • 3.2 SECONDARY RESEARCH
  • 3.3 PRIMARY RESEARCH
  • 3.4 BREAKDOWN OF PRIMARY RESPONDENTS
  • 3.5 FORECASTING TECHNIQUES
  • 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
    • 3.6.1 BOTTOM-UP APPROACH
    • 3.6.2 TOP-DOWN APPROACH
  • 3.7 DATA TRIANGULATION
  • 3.8 VALIDATION

4 MARKET DYNAMICS

  • 4.1 OVERVIEW
  • 4.2 DRIVERS
    • 4.2.1 INCREASING PREVALENCE OF DYSLEXIA
    • 4.2.2 INCREASING APP DEVELOPMENT ACTIVITIES TO TREAT DYSLEXIA
    • 4.2.3 GROWING NUMBER OF VITUAL REALITY-BASED EDUCATIONAL SOFTWARE
  • 4.3 RESTRAINT
    • 4.3.1 LACK OF AWARENESS ABOUT DYSLEXIA, ITS SYMPTOMS AND UNDERDIAGNOSIS
  • 4.4 OPPORTUNITY
    • 4.4.1 COLLABORATION WITH SCHOOLS, COLLEGES AND NON PROFIT ORGANIZATIONS

5 MARKET FACTOR ANALYSIS

  • 5.1 VALUE CHAIN ANALYSIS
    • 5.1.1 RESEARCH & DEVELOPMENT
    • 5.1.2 MANUFACTURING
    • 5.1.3 DISTRIBUTION
    • 5.1.4 MARKETING & SALES
    • 5.1.5 POST-SALES MONITORING
    • 5.1.6 INPUTS
    • 5.1.7 SOFTWARE DEVELOPMENT PROCESSES
    • 5.1.8 OUTPUT
    • 5.1.9 MARKETING AND DISTRIBUTION
    • 5.1.10 POST-SELLING SERVICES
  • 5.2 PORTER'S FIVE FORCES MODEL
    • 5.2.1 BARGAINING POWER OF BUYERS
    • 5.2.2 BARGAINING POWER OF SUPPLIERS
    • 5.2.3 THREAT OF NEW ENTRANTS
    • 5.2.4 THREAT OF SUBSTITUTES
    • 5.2.5 INTENSITY OF RIVALRY
  • 5.3 IMPACT OF COVID-19
  • 5.4 DYSLEXIA DIAGNOSIS
  • 5.5 DYSLEXIA TREATMENT
  • 5.6 STANDARD PAPER TESTS VS ELECTRONIC VERSIONS
    • 5.6.1 TESTS FOR DYSLEXIA AND LEARNING DISABILITIES (PRE-SCHOOLERS)

6 GLOBAL DYSLEXIA TREATMENT & DIAGNOSIS MARKET BY TYPE

  • 6.1 OVERVIEW
  • 6.2 PHONOLOGICAL DYSLEXIA
  • 6.3 SURFACE DYSLEXIA
  • 6.4 OTHERS

7 GLOBAL DYSLEXIA TREATMENT & DIAGNOSIS MARKET BY TREATMENT & DIAGNOSIS

  • 7.1 OVERVIEW
  • 7.2 TREATMENT
    • 7.2.1 MEDICATIONS
      • 7.2.1.1 ANTIHISTAMINES
      • 7.2.1.2 CENTRAL NERVOUS STIMULANT
      • 7.2.1.3 ANTI-MYOCLONIC
      • 7.2.1.4 ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) DRUG
      • 7.2.1.5 OTHERS
    • 7.2.2 TOOLS
      • 7.2.2.1 E-READERS AND TABLETS
      • 7.2.2.2 APPS
      • 7.2.2.3 SMARTPENS
      • 7.2.2.4 OTHERS
  • 7.3 DIAGNOSIS
    • 7.3.1 PAPER-BASED
    • 7.3.2 DIGITAL-BASED

8 GLOBAL DYSLEXIA TREATMENT & DIAGNOSIS MARKET BY END USER

  • 8.1 OVERVIEW
  • 8.2 SPECIALTY CENTER
  • 8.3 HOME CARE
  • 8.4 HOSPITALS & CLINICS
  • 8.5 OTHERS

9 GLOBAL DYSLEXIA TREATMENT & DIAGNOSIS MARKET, BY REGION

  • 9.1 OVERVIEW
  • 9.2 NORTH AMERICA
    • 9.2.1 US
    • 9.2.2 CANADA
  • 9.3 EUROPE
    • 9.3.1 GERMANY
    • 9.3.2 UK
    • 9.3.3 FRANCE
    • 9.3.4 ITALY
    • 9.3.5 SPAIN
    • 9.3.6 REST OF EUROPE
  • 9.4 ASIA PACIFIC
    • 9.4.1 CHINA
    • 9.4.2 JAPAN
    • 9.4.3 INDIA
    • 9.4.4 AUSTRALIA
    • 9.4.5 SOUTH KOREA
    • 9.4.6 REST OF ASIA-PACIFIC
  • 9.5 REST OF THE WORLD
    • 9.5.1 LATIN AMERICA
    • 9.5.2 MIDDLE EAST
    • 9.5.3 AFRICA

10 COMPETITIVE LANDSCAPE

  • 10.1 COMPETITIVE OVERVIEW
  • 10.2 MAJOR PLAYERS IN THE GLOBAL DYSLEXIA TREATMENT MARKET
  • 10.3 MAJOR GROWTH STRATEGIES IN THE GLOBAL DYSLEXIA TREATMENT MARKET
  • 10.4 COMPETITIVE BENCHMARKING
  • 10.5 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL DYSLEXIA TREATMENT MARKET
  • 10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
    • 10.6.1 NEW PRODUCT DEVELOPMENTS/LAUNCHES
    • 10.6.2 COLLABORATIONS/EXPANSIONS/PARTNERSHIPS/INVESTMENTS
  • 10.7 MAJOR PLAYERS FINANCIAL MATRIX
    • 10.7.1 REVENUE OF MAJOR PLAYERS, 2020
    • 10.7.2 R&D EXPENDITURE, 2020

11 COMPANY PROFILES

  • 11.1 PFIZER INC.
    • 11.1.1 COMPANY OVERVIEW
    • 11.1.2 FINANCIAL OVERVIEW
    • 11.1.3 PRODUCTS OFFERED
    • 11.1.4 KEY DEVELOPMENTS
    • 11.1.5 SWOT ANALYSIS
    • 11.1.6 KEY STRATEGIES
  • 11.2 SPEECHIFY INC.
    • 11.2.1 COMPANY OVERVIEW
    • 11.2.2 FINANCIAL OVERVIEW
    • 11.2.3 PRODUCTS OFFERED
    • 11.2.4 KEY DEVELOPMENTS.
    • 11.2.5 KEY STRATEGIES
  • 11.3 JUBILANT PHARMA LIMITED
    • 11.3.1 COMPANY OVERVIEW
    • 11.3.2 FINANCIAL OVERVIEW
    • 11.3.3 PRODUCTS/SERVICES OFFERED
    • 11.3.4 KEY DEVELOPMENTS
    • 11.3.5 KEY STRATEGIES
  • 11.4 LINGIT AS
    • 11.4.1 COMPANY OVERVIEW
    • 11.4.2 FINANCIAL OVERVIEW
    • 11.4.3 PRODUCTS OFFERED
    • 11.4.4 KEY DEVELOPMENTS
    • 11.4.5 KEY STRATEGIES
  • 11.5 SOLI
    • 11.5.1 COMPANY OVERVIEW
    • 11.5.2 FINANCIAL OVERVIEW
    • 11.5.3 PRODUCTS OFFERED
    • 11.5.4 KEY DEVELOPMENTS
    • 11.5.5 KEY STRATEGIES
  • 11.6 NOVARTIS AG
    • 11.6.1 COMPANY OVERVIEW
    • 11.6.2 FINANCIAL OVERVIEW
    • 11.6.3 PRODUCTS/SERVICES OFFERED
    • 11.6.4 KEY DEVELOPMENTS
    • 11.6.5 SWOT ANALYSIS
    • 11.6.6 KEY STRATEGIES
  • 11.7 LYFTA
    • 11.7.1 COMPANY OVERVIEW
    • 11.7.2 FINANCIAL OVERVIEW
    • 11.7.3 PRODUCTS/SERVICES OFFERED
    • 11.7.4 KEY DEVELOPMENTS
    • 11.7.5 KEY STRATEGIES
  • 11.8 GLAXOSMITHKLINE
    • 11.8.1 COMPANY OVERVIEW
    • 11.8.2 FINANCIAL OVERVIEW
    • 11.8.3 PRODUCTS OFFERED
    • 11.8.4 KEY DEVELOPMENTS
    • 11.8.5 SWOT ANALYSIS
    • 11.8.6 KEY STRATEGIES
  • 11.9 TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • 11.9.1 COMPANY OVERVIEW
    • 11.9.2 FINANCIAL OVERVIEW
    • 11.9.3 PRODUCTS/SERVICES OFFERED
    • 11.9.4 KEY DEVELOPMENTS
    • 11.9.5 SWOT ANALYSIS
    • 11.9.6 KEY STRATEGIES
  • 11.10 ELI LILLY & COMPANY
    • 11.10.1 COMPANY OVERVIEW
    • 11.10.2 FINANCIAL OVERVIEW
    • 11.10.3 PRODUCTS/SERVICES OFFERED
    • 11.10.4 KEY DEVELOPMENTS
    • 11.10.5 SWOT ANALYSIS
    • 11.10.6 KEY STRATEGIES
  • 11.11 RPG LIFE SCIENCES LTD
    • 11.11.1 COMPANY OVERVIEW
    • 11.11.2 FINANCIAL OVERVIEW
    • 11.11.3 PRODUCTS/SERVICES OFFERED
    • 11.11.4 KEY DEVELOPMENTS
    • 11.11.5 KEY STRATEGIES
  • 11.12 HOPALAI D.O.O.
    • 11.12.1 COMPANY OVERVIEW
    • 11.12.2 FINANCIAL OVERVIEW
    • 11.12.3 PRODUCTS/SERVICES OFFERED
    • 11.12.4 KEY DEVELOPMENTS
    • 11.12.5 KEY STRATEGIES

12 APPENDIX

  • 12.1 REFERENCES
  • 12.2 RELATED REPORTS